OMass has raised $310 million to advance a drug for congenital adrenal hyperplasia, a rare endocrine disorder. The molecule is being developed as a potential alternative to Neurocrine Biosciences' therapy, which is currently the only FDA-approved treatment for the condition.
The startup's candidate could face additional competition from Vertex Pharmaceuticals, which may have a drug candidate from a recent acquisition. With multiple developers pursuing the space, the treatment landscape for congenital adrenal hyperplasia could shift if OMass's therapy succeeds in development.